Clinical Trial Update: A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of 177Lu-DOTATATE and nivolumab in neuroendocrine tumours and neuroendocrine carcinomas.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinomas
• Neuroendocrine Tumours

Drugs mentioned

• 177Lu-DOTATATE (Lutetium-177 dotatate)
• nivolumab (nivolumab)

Snippet

Sponsor: Fundación de investigación HM | Conditions: Neuroendocrine Tumours (NET), Neuroendocrine Carcinomas (NEC) | Phase 2 | Status: UNKNOWN